We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Effective and Tolerable Treatment of Advanced Basal Cell Carcinoma With Vismodegib Despite Renal Insufficiency ONLINE FIRST

Lara Valeska Maul, MD1; Katharina C. Kähler, MD1; Axel Hauschild, MD1
[+] Author Affiliations
1Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
JAMA Dermatol. Published online December 30, 2015. doi:10.1001/jamadermatol.2015.4592
Text Size: A A A
Published online


This case report describes treatment of advanced basal cell carcinoma with vismodegib in the context of renal insufficiency.

Recently, the hedgehog inhibitor vismodegib (Erivedge; Genentech) has demonstrated efficacy in the treatment of locally advanced and metastatic basal cell carcinoma (BCC).1,2 Almost all BCC contains genetic alterations in the sonic hedgehog signaling pathway. Most mutations affect the function of patched homologue 1, which normally inhibits the signaling activity of the transmembrane protein smoothened homologue. In a phase 1 study of vismodegib,1 a 58% response rate among 33 patients with advanced BCC was observed. The approval of vismodegib treatment at 150 mg/d was based on results from the phase 2 study.2 That study found the response rate for metastatic BCC to 30% and for locally advanced BCC, 43%, with a complete response in 21% of the cases. Common adverse events reported by more than 30% of patients were muscle spasms, alopecia, dysgeusia, weight loss, and fatigue.

Figures in this Article

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption
Vismodegib Treatment of Locally Advanced, Ulcerated Basal Cell Carcinoma of the Right Midface

A, Osseous and muscular tumor infiltration of both orbits and the nasal bridge before vismodegib treatment initiation. B, Conversion of secreting tissue into dry tumor tissue after 11 months of treatment with vismodegib.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles